Recursion Pharmaceuticals (RXRX) Other Non-Current Assets (2020 - 2025)
Historic Other Non-Current Assets for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $14.7 million.
- Recursion Pharmaceuticals' Other Non-Current Assets rose 12116.46% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 12116.46%. This contributed to the annual value of $8.8 million for FY2024, which is 3312.72% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Other Non-Current Assets is $14.7 million, which was up 12116.46% from $9.4 million recorded in Q2 2025.
- Recursion Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $14.8 million during Q1 2025, with a 5-year trough of $35000.0 in Q3 2021.
- In the last 5 years, Recursion Pharmaceuticals' Other Non-Current Assets had a median value of $7.9 million in 2022 and averaged $7.5 million.
- Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 2319714.29% in 2022, then tumbled by 1630.05% in 2023.
- Recursion Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $8.7 million in 2021, then dropped by 8.77% to $7.9 million in 2022, then dropped by 16.3% to $6.6 million in 2023, then skyrocketed by 33.13% to $8.8 million in 2024, then skyrocketed by 66.13% to $14.7 million in 2025.
- Its Other Non-Current Assets was $14.7 million in Q3 2025, compared to $9.4 million in Q2 2025 and $14.8 million in Q1 2025.